The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload


Sivgin S., Baldane S. , AKYOL G. , Keklik M. , KAYNAR L. , Kurnaz F. , ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.49, ss.295-301, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 49 Konu: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.transci.2013.07.004
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Sayfa Sayıları: ss.295-301

Özet

Introduction: Iron overload (10) has been shown to be an important cause of mortality and morbidity in patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). This study aimed to evaluate the possible effect of oral iron-chelation treatment (deferasirox) on survival in alloHSCT recipients in the posttransplant period.